Zhongheng Seeks To Raise Price Of Essential Anti-clotting Drug
This article was originally published in PharmAsia News
Executive Summary
WuZhou Zhongheng has raised the prices of its major product Xueshuantong, an anti-clotting drug, in a number of provinces in order to cover the costs of Panax Notoginseng which surged nearly fivefold since November last year